bioAffinity Technologies(BIAF) - 2024 Q3 - Quarterly Results

Exhibit 99.1 News Release bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician of ices signed increased 75% over Q2 2024 Reaf irmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary SAN ANTONIO, Texas (November 14, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on t ...